494 related articles for article (PubMed ID: 32883316)
1. Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation.
Topatana W; Juengpanich S; Li S; Cao J; Hu J; Lee J; Suliyanto K; Ma D; Zhang B; Chen M; Cai X
J Hematol Oncol; 2020 Sep; 13(1):118. PubMed ID: 32883316
[TBL] [Abstract][Full Text] [Related]
2. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
3. Synthetic lethal vulnerabilities of cancer.
Fece de la Cruz F; Gapp BV; Nijman SM
Annu Rev Pharmacol Toxicol; 2015; 55():513-31. PubMed ID: 25340932
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
5. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
Bortlíková L; Müller P; Vojtěšek B; Rak V; Svoboda M
Klin Onkol; 2019; 32(Supplementum 3):19-24. PubMed ID: 31627702
[TBL] [Abstract][Full Text] [Related]
7. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
Bhattacharjee S; Nandi S
IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
[TBL] [Abstract][Full Text] [Related]
9. DNA Double Strand Break Repair - Related Synthetic Lethality.
Toma M; Skorski T; Sliwinski T
Curr Med Chem; 2019; 26(8):1446-1482. PubMed ID: 29421999
[TBL] [Abstract][Full Text] [Related]
10. Synthetic Lethality and Cancer - Penetrance as the Major Barrier.
Ryan CJ; Bajrami I; Lord CJ
Trends Cancer; 2018 Oct; 4(10):671-683. PubMed ID: 30292351
[TBL] [Abstract][Full Text] [Related]
11. Identifying synthetic lethal targets using CRISPR/Cas9 system.
Dhanjal JK; Radhakrishnan N; Sundar D
Methods; 2017 Dec; 131():66-73. PubMed ID: 28710008
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic synthetic lethality approaches in cancer therapy.
Yang H; Cui W; Wang L
Clin Epigenetics; 2019 Oct; 11(1):136. PubMed ID: 31590683
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethality on drug discovery: an update on cancer therapy.
Yar MS; Haider K; Gohel V; Siddiqui NA; Kamal A
Expert Opin Drug Discov; 2020 Jul; 15(7):823-832. PubMed ID: 32228106
[TBL] [Abstract][Full Text] [Related]
14. Synthetic lethality as an engine for cancer drug target discovery.
Huang A; Garraway LA; Ashworth A; Weber B
Nat Rev Drug Discov; 2020 Jan; 19(1):23-38. PubMed ID: 31712683
[TBL] [Abstract][Full Text] [Related]
15. Synthetic lethal interaction between oxidative stress response and DNA damage repair in the budding yeast and its application to targeted anticancer therapy.
Choi JE; Chung WH
J Microbiol; 2019 Jan; 57(1):9-17. PubMed ID: 30594981
[TBL] [Abstract][Full Text] [Related]
16. The power and the promise of synthetic lethality for clinical application in cancer treatment.
Liu QW; Yang ZW; Tang QH; Wang WE; Chu DS; Ji JF; Fan QY; Jiang H; Yang QX; Zhang H; Liu XY; Xu XS; Wang XF; Liu JB; Fu D; Tao K; Yu H
Biomed Pharmacother; 2024 Mar; 172():116288. PubMed ID: 38377739
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibition as a prototype for synthetic lethal screens.
Liu X
Methods Mol Biol; 2013; 986():123-37. PubMed ID: 23436410
[TBL] [Abstract][Full Text] [Related]
18. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.
Oei AL; van Leeuwen CM; Ahire VR; Rodermond HM; Ten Cate R; Westermann AM; Stalpers LJA; Crezee J; Kok HP; Krawczyk PM; Kanaar R; Franken NAP
Oncotarget; 2017 Apr; 8(17):28116-28124. PubMed ID: 28427225
[TBL] [Abstract][Full Text] [Related]
19. Synthetic lethality guiding selection of drug combinations in ovarian cancer.
Heinzel A; Marhold M; Mayer P; Schwarz M; Tomasich E; Lukas A; Krainer M; Perco P
PLoS One; 2019; 14(1):e0210859. PubMed ID: 30682083
[TBL] [Abstract][Full Text] [Related]
20. A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
Srivas R; Shen JP; Yang CC; Sun SM; Li J; Gross AM; Jensen J; Licon K; Bojorquez-Gomez A; Klepper K; Huang J; Pekin D; Xu JL; Yeerna H; Sivaganesh V; Kollenstart L; van Attikum H; Aza-Blanc P; Sobol RW; Ideker T
Mol Cell; 2016 Aug; 63(3):514-25. PubMed ID: 27453043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
